6533b85bfe1ef96bd12bbf2d
RESEARCH PRODUCT
Update on autoimmune hepatitis
Andreas TeufelPeter R. GalleStephan Kanzlersubject
AdultHyperglobulinemiaAzathioprineAutoimmune hepatitisDiseaseAntibodiesLiver diseaseLife ExpectancyAdrenal Cortex Hormonesimmune system diseasesPrednisonemedicineHumansSurvivorsChildHepatitisGenome Humanbusiness.industryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIThyroiditis AutoimmuneGastroenterologyAutoantibodyDNAGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneEditorialImmunoglobulin GImmunologybusinessImmunosuppressive AgentsMicrosatellite Repeatsmedicine.drugdescription
Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology that occurs in children and adults of all ages. Characteristics are its autoimmune features, hyperglobulinemia (IgG), and the presence of circulating autoantibodies, as well as a response to immunosuppressant drugs. Current treatment consists of prednisone and azathioprine and in most patients this disease has become very treatable. Over the past 2 years, a couple of new insights into the genetic aspects, clinical course and treatment of AIH have been reported, which will be the focus of this review. In particular, we concentrate on genome-wide microsatellite analysis, a novel mouse model of AIH, the evaluation of a large AIH cohort for overlap syndromes, suggested novel criteria for the diagnosis of AIH, and the latest studies on treatment of AIH with budenoside and mycophenolate mofetil.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-03-07 | World Journal of Gastroenterology |